CUMULATIVE INDEX 2000

Volume 16

February	COMMUNICATION BETWEEN OLDER PATIENTS AND THEIR PHYSICIANS, pages 1–209
May	DEATH AND DYING, pages 211–405
August	HEART FAILURE IN THE ELDERLY, pages 407–682
November	SUBACUTE CARE FOR SENIORS, pages 683–910

Note: Page numbers of article titles are in **boldface** type.

ACE inhibitors. See *Angiotensin-converting enzyme inhibitors.*
Acetaminophen, for older adults, 275
  in pain management, 862
Acute care, long-term, regional weaning centers and, 745–749
β-Adrenergic blockers, in atrial fibrillation, 600
β-Adrenergic modulation, with aging, 433–437
Adrenergic receptor blocking agents, in heart failure caused by systolic dysfunction, 524–525
Adult(s), older. See *Older patient(s).*
  over age of 65, leading causes of death and death rates for, 178–179
    life expectancy of, 178
    living arrangements of, 178
Advance care planning discussions, approach for, 245–252
  as undesirable for specific scenarios, 243
  beginning of, 246–247
  choosing surrogate decision makers and, 250
  conduction of, 244–245
  difficulty in, for doctors, 245–246
    for patients, 246
  documenting advance directives in, 250–251
  effective communication for, 251
  eliciting of preferences in, 248–250
  goals of, 243–245
  influence of patient on care and, 244
  preparation for, 245
  provision of information for, 247
  provision of options in, 248–249
  terminology to use in, 250
Advance directive(s), benefits of, 241
  case illustrating, 239, 251–252
    vagueness in, 240
  dementia and, 256–258, 260
  discussion of, 189–190
  execution of, decisional capacity needed for, 260–261
  goal of, 241–242
  implications of, and recommendations for, 265–266
  older adults with dementia and, **255–268**
  patients' preferences in, physician adherence to, 191–192
  physician unaware of, 240
  problems associated with, 242–243
  talking to older adults about, **239–254**
  types of, 241
  understanding and interpretation of, by patient and physician, 190–191
Age, and aging, attitudes toward, 3–4
Aging, cardiovascular, in health, **419–443**
  of US population, demographic trends in, 178
  perceptions and attitudes of, as influence on communication, 164, 173
Agism, 3–4
Alcohol abstinence, in heart failure, 478–479
Alcohol abuse, in elderly with heart disease, 650–651
Alginates, 795

Alzheimer's disease, and other dementias, implications for physician communication, **153–173**
communication strategies in, 159–164
dementia in, 373–374
need for advance health care planning in, 258
Amputation, lower-extremity, in diabetes, 847–848
Analgesic ladder, of World Health Organization, 274
Analgesics, adjuvant, in pain, 885
continuous infusions of, 868
in pain management in subacute care, 861–868
Aneurysmectomy, in ischemic cardiomyopathy, 572
Angiogenesis, in ischemic cardiomyopathy, 572
Angiotensin-converting enzyme inhibitors, in heart failure caused by systolic dysfunction, 520–523
in heart failure complicating acute myocardial infarction, 538–539
Angiotensin II receptor blockers, in heart failure caused by systolic dysfunction, 523–524
Anorexia, of aging, 817–819
physiologic aspects of, 817, 818
Antiarrhythmic drugs, in heart failure caused by systolic dysfunction, 527
Anticholinergic drugs, delirium associated with, 376
Anticoagulants, in heart failure caused by systolic dysfunction, 527
Antidepressants, in depression, 343–344, 349–350
in pain, 867
Anti-inflammatory drugs, nonsteroidal. See *Nonsteroidal anti-inflammatory drugs.*
Antimuscarinic agents, in gastrointestinal obstruction, 330–332
Antisecretory agents, in gastrointestinal obstruction, **327–334**
Anxiety, in elderly with heart disease, 655–656
in pain, 856
Aortic stenosis, and aortic valve replacement, in elderly, 556
and mitral regurgitation, evaluation in, 575
prostheses in, 576
repair of, 576
results of, 575
Aortic valve replacement, alternatives to, 556–558
Appetite-enhancing medications, 825
Arrhythmias, management of, **593–618**
treatment of, in heart failure complicating acute myocardial infarction, 542–543
ventricular, nonsustained, incidence, prognosis, and treatment of, 606–608
sustained, incidence, prognosis, and treatment of, 605–606
Arterial stenosis, renal, congestive heart failure in, 561
Artificial nutrition and hydration, decisions concerning, legal and ethical aspects of, 314–315
withholding and withdrawing of, 313
Aspiration pneumonia, percutaneous endoscopic gastrostomy tube and, 319–320
Aspirin, for stroke prevention in atrial fibrillation, 597–598
Atrial fibrillation, control of heart rate in, 599–601
etiologies of, 593–594
impact of, 594–595
initial management of, 595–596
long-term management of, 596
prevalence of, 593
prevention of stroke in, 596–599
Atropine, in gastrointestinal obstruction, 331

Bacteremia, from pressure ulcers, 797
Bacterial contamination, protection of wounds from, 791–793
Bad news, breaking of, at end of life, 196–197
Balanced Budget Act of 1997, case management system and, 770
cost containment of health care delivery under, 769–770
delivery process, changes in, 766–768
ethical and social responsibility and, 771–773
financial impact of, 758–766
implications of, 757, **757–773**
objective of, 757
survival and growth under, reengineering strategies for, 768–770
Batista ventriculectomy, in ischemic cardiomyopathy, 572
Behavioral therapy, in pain, 870
Benzodiazepines, in pain management, 283
Biguanides, in diabetes, 840–841
Bisphosphonates, in pain management, 284
β-Blockers, in heart failure complicating acute myocardial infarction, 540–541

Body language, awareness of, by dementia patient, 161, 169
Bradyarrhythmias, and pacing, 609–610
Brain failure, and urinary incontinence in heart failure patients, 644

Cachexia, 820, 849
  cardiac, heart failure in elderly and, 645
Calcium channel blockers, in atrial fibrillation, 600
  in heart failure caused by systolic dysfunction, 526–527
  in heart failure complicating acute myocardial infarction, 541–542
Cancer patients, delirium in, assessment methods for, 361–362
  discussion of life expectancy with, 182
  health status models of, 876, 877
Carbamazepine, 867
Cardiac output, with aging, 428–429
Cardiac patients, elderly, cardiac rehabilitation and secondary prevention programs for, **619–629**
Cardiac rehabilitation. See *Rehabilitation, cardiac.*
Cardiac transplantation, in heart failure, 577–581
Cardiomyopathy, ischemic, angiogenesis in, 572
  evaluation of, 568–569
  revascularization in, 569–572
  ventricular remodeling in, 572–575
Cardiomyoplasty, dynamic, in ischemic cardiomyopathy, 573–574
Cardiopulmonary resuscitation, 670
  correlation between age and not wanting, 184
  description of, by physician, 183
  discussion of, with physician, 179, 180
  overestimation of success of, 114
Cardiovascular aging, effects of lifestyle on, 437–441
  in health, **419–443**
Cardiovascular function, age-related changes in, 422–431
  resting, effect of age on, 491–492
Cardiovascular reserve function, 431–441
Cardiovascular system, normal changes in, with aging, 489–493
  structure of, 420–422
    with aging, 429–431
Cardiovascular testing, in heart failure in elderly, 449
Care, level of, for patient with acute illness or injury, determination of, 695–696
  managed. See *Managed care.*
  subacute. See *Subacute care.*
Care delivery, integrated system of, promotion of, 18–19
  quality of, measurement of, 387, 388–389
Care plans, involvement of caregivers in, 17
Caregiver(s), and patient, relationship of, perception of, 17
  as influence on dynamics of patient–physician relationship, 28
  family, characteristics of, 52
  in pain assessment, 860–861
  involvement of, in diagnosis and care plans, 17
  nursing home, perspectives on dying in long-term care facilities, 226–230
  roles of, during process of dying, 233–235
Caregiving, effects of, 52–53
  issues related to, family assistance in, tasks in, 51–52
    geriatric medical encounter and, **51–60**
Case management system, Balanced Budget Act and, 770
Certified nursing assistants, in long-term care facilities, 226
Chemotherapeutic agents, causing delirium, 363
Chlorpromazine, in delirium, 365–366, 377
Chromium deficiency, 827
Circulatory support, mechanical, as bridge to recovery, in heart failure, 582–584
  as bridge to transplantation, 581–582
  permanent implantation of, in heart failure, 584–587
Clinical pragmatism, 72–75
  and case presented to ethics case consultation service, 75–80
  ethics consultation, and elderly patients, **71–81**
  methodology of, 72
  philosophical roots of, 72
  steps to, 73
Cognition, of dementia patient, modification of communication and, 160, 168–169
Cognitive disturbances, opioid-induced, 282
Cognitive impairment. See also *Dementia.*
  communication and, 5–6
  management of family–doctor–patient relationship in, 55–57
  pain assessment in, 859–860
Cognitive therapy, in pain, 869–870
Communication, between older patients and their physicians. See *Older patient–physician communication.*
  cognitive impairment and, 5–6
  during hospitalization, patterns of, 113
    structure of, 111–113

Communication (*continued*)
E-mail, 19–20
effective, in medical encounter, empowering older patients for, **61–70**
effects of medications on, 162, 170
factors influencing, 159, 172
functional deficits and, 6–7
impact of health status on, 100–102
impaired by environment, 161–162
implications of, for physician, in Alzheimer's disease and other dementias, **153–173**
in dementia, 154–156
considerations for enhancement of, 158–159
intra- and intergenerational, with dementia patients, 163, 172
loss of hearing and, 5
loss of vision and, 5
patterns of, of older patients, 98–100
perceptions and attitudes of aging as influence on, 164, 173
style of, in dementia, 163
telephone, 19
Confusion assessment method diagnostic algorithm, 293–294
Congestive heart failure. See *Heart failure.*
Constipation, as complication of opioid drugs, 864–865
Conversation, strategies for, in dementia, 162, 170–171
Coronary artery disease, congestive heart failure in, 550–555
Coronary flow, with aging, 426–428
Cost containment, of health care delivery, under Balanced Budget Act, 770
Counseling, in pain management, 273
Culture and ethnicity, effects of, on communication with dementia patients, 163, 172–173
Cyclooxygenase enzymes, isoforms of, for older adults, 275
nonsteroidal anti-inflammatory drugs and, 862–863
Cytochrome P450, inhibition of, by serotonin-specific reuptake inhibitors, 345–347
Cytokines, and food intake, 819–820, 849

Death(s), and dying, **211–400**
management of patients with end-stage disease, **875–893**
bad characteristics of, in long-term care facilities, 232–233
good, definition of, 388
good characteristics of, in long-term care facilities, 233
impending, signs of, care in, 887, 888
in long-term care population, predicting of, 231–232
Decision makers, surrogate, 241
Decision making, by patient, criteria for, 184–185
patient–physician communication and, 27–28
capacity for, needed to make advance directives, 260–261
medical, in long-term care facilities, 220
integrating psychosocial factors into, 15–16
Dehydration, in subacute care, 826
Delirium, and dementia, compared, 360–361
as sign of physiologic disturbance, 358
assessment of, in pain management, 271–272
causes of, assessment of, 362–364
in subacute care, 717
clinical features of, 358–359
definition of, 376
diagnosis of, 358–359
workup in, 363
differential diagnosis of, 360–361
DSM-IV criteria for, 359
impediments to recognition and treatment of, 358
in advanced dementia, 375–377
in age-related heart failure, 636–637
in end-stage disease, 886
in terminal illness, **357–372**
management of, 362
controversies in, 367–368
incidence of, in hospitalized patients, 357–358
medical causes of, 272
medications implicated in, 272
nonpharmacologic interventions in, 364
opioid-induced, 282
pharmacologic interventions in, 364–366, 367
discussion with family concerning, 368
prevalence of, 357
resulting from medical condition, criteria for, 271–272
screening for, diagnostic scales in, 361–362
subtypes of, 359–360
symptoms of, 271
Delirium assessment scales, 290–311
Delirium rating scale, 294–298
Delirium symptom interview, 298–311
Dementia, advance directives and, 256–258, 260
advance planning for people with, 258–260
models of, 261–263

advanced, agitation and delirium in, 375–377
and hospice care, 380–382
delusions and hallucinations in, 377–378
depression in, 378–379
domains of suffering from, 381
fever in, 379–380
or dysphagic stroke, tube feeding in, 318–321
pain in, 378
palliative care for, **373–386**
poor sleep in, 379
Alzheimer's disease and, implications of, for physician communication, **153–173**
and delirium, compared, 360–361
assessment of language and speech in, 156
biases and beliefs concerning, 259
caregiving in, 55–56
communication in, considerations for enhancement of, 158–159
conditions underlying, 373
decision making in, 255
definition of, 153, 373
demographics and diagnosis of, 256
end-stage, 374–375
complications of, 379–380
families of patients with, care for, 384–385
family guilt and ambivalence in, 384
management of, 375
palliative care in, specific challenges in, 382–384
presumptive treatment in, 384
prognostic uncertainty in, 382–383
signs and symptoms of, 374–375
treatment decisions in, 383
guidelines for determination of planning capacity in, 258
hospice admission guidelines for, based on Functional Assessment Staging Scale, 382
hospice care and, 264–265, 878
hospitalization in, 260
in age-related heart failure, 634–636
lack of markers of disease progression in, 259
language and speech in, 155
and communication in, 154–156
National Hospice Organization and, 382
pain management in, 272
speech-language pathologists and, 157
stages of, 256
strategies in, 157–164
uneven effectiveness of, 158
types of, 153
Depression, and urinary incontinence in heart failure patients, 644
antidepressant medication in, 343–344
as problem in subacute care, 716
disease-related factors and, 341–342
electroconvulsive therapy in, 352
existential concerns in, 342
general considerations in, 336
in advanced dementia, 378–379
in dementia and delirium, 342
in diabetes, 849
in dying older patients, **335–356**
low social support and, 341
sex differences in, 339
in elderly with heart disease, 651–654
treatment of, 654–655
in palliative care setting, assessment of, 337–338
in terminal illness, 336–339
management of, 343
loss of interest or pleasure in activities in, 338
major, in elderly with heart disease, 653
monoamine oxidase inhibitors in, 351
norepinephrine dopamine modulators in, 348–349
pain and, 341
physical disability and, 341–342
psychostimulants in, 350
reversible inhibitors of monoamine oxidase A in, 349
risk factors for, 339–341
serotonin antagonist reuptake inhibitors in, 348
serotonin norepinephrine reuptake inhibitors in, 347–348
serotonin-specific reuptake inhibitors in, 344–347
somatic symptoms in, 338
symptom severity thresholds in, 339, 340
treatment-related factors in, 342
tricyclic antidepressants in, 349–350
Desipramine, 867
in depression, 349–350
Dextroamphetamine, in depression, 351
Diabetes mellitus, acute complications of, 843–845
age-related considerations in, 835–837
as risk factor for hypertension, 846–847
cardiovascular complications in, 833
classification of, 834–835
depression in, 849
dietary therapy in, 838–839
exercise in, 839
falls related to, 846
foot wounds in, 847–848
geriatric syndromes related to, 846–849
glycemic targets in, 836
hypertensive treatment in, 847

Diabetes mellitus (*continued*)
initial approach and baseline assessment in, 837–838
insulin requirements in, 834, 839, 841–843
laboratory tests in, 837
malnutrition in, 848–849
management of, 827, 838–849
in subacute care setting, 717, **833–852**
essential processes of, 836–837
initial approach in, 838
oral agents in, 839
physical examination in, 837
Diabetic ketoacidosis, 845
Diabetic neuralgia, management of, 867–868
Diabetic ulcers, amputations due to, 798
maintenance of moist environment in, 786–787
nutritional therapy in, 786
promotion of wound healing in, 791
protection from bacterial contamination, 793
removal of necrotic debris from, 789
shielding of, from further damage, 788
topical wound dressing for, 793–795
Diastolic function, and exercise, in elderly, 492
assessment of, in heart failure in elderly, 465–466
classification of, 469
Diet, as factor in heart failure, 478–480
management of, in diabetes, 838–839
Dietary supplements, use of, in heart failure, 479–480
Digitalis, in atrial fibrillation, 599–600
Digoxin, in heart failure caused by systolic dysfunction, 525–526
in heart failure complicating acute myocardial infarction, 542
Director of nursing, in long-term care facility, 227
Disclosure, principles defining, behavior of physicians regarding, 181–182
Disease, chronic, health status models of, 876, 877
Diuretics, and urinary incontinence in heart failure patients, 642–643
in heart failure caused by systolic dysfunction, 517–520
in heart failure complicating acute myocardial infarction, 537–538
Do-not-hospitalize orders, 264
Do-not-intubate orders, 241
Do-not-resuscitate orders, 241
and end of life, 670–673
discussion about, 181–182
Doppler echocardiography, in heart failure in elderly, 465
Dor ventricular dilatation, in ischemic cardiomyopathy, 572
Drug dependence, 865
Drug therapy, of heart failure caused by systolic dysfunction in elderly, **513–534**
Drugs. See *Medications.*
Dying. See also *Death(s), and dying.*
process of, caregiver roles during, 233–235
certified nursing assistant and, 233–235
nurses and, 233–234
physicians in, 234
understanding of, 176
Dying patient(s), care of, in long-term care facilities, **225–237**
in long-term care facilities, nursing home caregivers' perspectives on, 230–235
older, depression in, **335–356**
with advanced malignancy, hydration in, 315–318

E-mail communication, 19–20
Echocardiography, Doppler, in heart failure in elderly, 465
in diagnosis and management of heart failure in elderly, **457–476**
M-mode and two-dimensional, in heart failure in elderly, 459–467
treatment decisions guided by, in elderly, 472
Education, and dementia, 162, 171
Elderly, chronic ventilator dependence in, **735–755**
Elderly patients. See *Older patient(s).*
Electroconvulsive therapy, in depression, 352
Emotional health outcomes, patient–physician communication and, 31–32
Emotions, and communication in dementia, 162–163, 171
End of life, breaking of bad news at, 196–197
palliative care services at, 198
physician–older patient communication at, 113–116, **175–204**
case study of, 176–177
challenges of, 177–178
content and process of discussions about, 182–185
coordination of care for, 197–198
cultural factors and, 192–194
empirical research on, 179–193
enhancing of, 195–198
important topics of discussion for, 198–199

on quality of life and preferences, 185–186
practical issues in, 194–200
questions of life expectancy and, 182
with family members, 183
truth telling by physician at, 180–182, 197
End-of-life care, aggressiveness of, near death, 393–394
in heart failure in elderly, **663–675**
in long-term care facilities, 211–212
ethical issues in, 219–221
opportunities for improving, 217–219
problems associated with, 220–221
management of family–doctor–patient relationship in, 57–58
patient and family satisfaction with, 394
quality in, assessment of, approaches for, 395–397
conceptual model for, 388
five domains of, 669–670
measuring of, **387–400**
operationalizing of, 388–394
quality of life and outcome measure of, 392–393
self-determination and, 389–391
support for family and, 393
survival duration and, 393
symptom control and, 391–392
relief of pain in, 881
resource use and costs of, 394
End-of-life decision making, 668–669
effective, model to facilitate, 115
End-of-life issues, general, 664
patients' desires to speak to physician about, 179–180
related to heart failure in elderly, 664–665
End-stage disease, health care goals and values of treatment in, 879–880
management of patients with, **875–893**
Environment, communication-impaired, 161–162
modification of, for communication in dementia, 161, 170
Epidermal resurfacing, agents delaying, 790, 791
agents promoting, 790
Ethical and social responsibility, Balanced Budget Act and, 771–773
Ethical consultation, clinical pragmatism, and the elderly patient, **71–81**
Ethics case consultation service, clinical pragmatism and, 75–80
Ethics differential diagnosis, 72, 74, 78–79
Exercise(s), and diastolic function, in elderly, 492
in diabetes, 839
in elderly with heart disease, 657
in pain, 869
Falls, associated with heart failure in elderly, 633–634
causes of, and prevention of, in subacute care, 717, 718
related to diabetes, 846
Family, caregiver as member of, characteristics of, 52
doctor–patient relationship, management of, 54–59
in cognitive impairment, 55–57
in different cultural backgrounds, 59
in difficult families, 58
in end-of-life care, 57–58
in no family, 59
in geriatric medical encounter, 53–54
in pain assessment, 860–861
of patient at end of life, support for, 393
of patient with end-stage dementia, care for, 384–385
satisfaction of, with end-of-life care, 394
Fatigue, in end-stage disease, 886
Fentanyl, in pain management, 277
Fever, in advanced dementia, 379–380
Fluid restriction, in heart failure, 478
Food intake, cytokines and, 819–820, 849
Foot, wounds of, in diabetes, 847–848
Functional Assessment Staging scale, for evaluation of dementia and hospice admission, 382
Functional deficits, communication and, 6–7
Functional limitations, attention to, 16–17

Gastrointestinal fluid, gastrointestinal obstruction and, 328–329
Gastrointestinal obstruction, antisecretory agents in, **327–334**
cancers complicated by, 328
causes of, 328
gastrointestinal fluid and, 328–329
management of, 329–330
pathophysiology of, 327–328
Gastrostomy tube, percutaneous endoscopic. See *Percutaneous endoscopic gastrostomy tube.*
Gender, effect of, on communication in dementia, 163, 172
Geriatric care, and acute rehabilitation, future of, 781
Geriatric evaluation and management units, 776–777
acute rehabilitation services in, effectiveness of, **775–782**
Geriatric medical encounter, caregiving issues in, **51–60**
Geriatric medicine, 4–5
Geriatric nurse practitioners, in long-term care facility, 227

Geriatric population, and health care system, 84–85
Geriatric team, communicating with, 18
α-Glucosidase inhibitors, in diabetes, 841
Group care seasons, 19

Hallucinations, in advanced dementia, 377–378
  in delirium, 367
Haloperidol, in delirium, 282, 364, 376, 377
Health and health-related outcomes, influence of patient–physician communication on, **25–36**
Health care, delivery process, changes in, 766–768
  goals and values of treatment in end-stage disease, 879–880
Health care proxy, 257–258
  do-not-hospitalize orders and, 264
  execution of, guidelines lowering threshold for, 262–263
  Physician Order Form for Life Sustaining Treatment and, 263–264
  values history and, 263
Health status, impact of, on communication, 100–102
Hearing, impairment of, and heart failure in elderly, 637–638
  loss of, communication and, 5
Heart, aging, structure of, 421–422
  structure of, age-related changes in, 490–491
Heart disease, comprehensive modification of risk factors for, rationale for, 621–624
  susceptibility to, physiologic aspects of aging contributing to, 620–621
Heart failure, advanced, drug therapy of, 528–530
  cardiac transplantation in, 577–581
  cause of, and factors contributing to, evaluation of, 514–515
  complicating acute myocardial infarction. See *Myocardial infarction, acute, heart failure complicating.*
  definition of, 407–408
  epidemiology of, and prognosis of, 665–668
    and quality of care in, 480–482
  in elderly, **407–675**
    brain failure associated with, 634–637
    cardiovascular testing in, 449
    caused by systolic dysfunction, drug therapy of, **513–534**
    clinical manifestations of, and diagnostic assessment, and etiology of, **445–456**
    comorbidity in, **631–648**
    comprehensive care in, 482–484
    end-of-life care in, **663–675**
    epidemic, in future, 414–415
    etiology of, 412
      determination of, 450–454
      differential diagnosis of, 458–459
    falls and postural hypotension associated with, 633–634
    incidence of, 409–410
    initial diagnostic testing in, 514–515
    linking of, to core concepts in geriatrics, 632–633
    physical findings in, 448–449
    prevalence of, 408–409
    prognosis and mortality in, 410–412
    prognosis determination in, 471–472
    psychosocial considerations in, **649–661**
    risk factors for, and prevention of, 412–414
    sensory deprivation and, 637–639
    symptoms of, 447–448
  interventional therapy in management of, **549–566**
  mechanical circulatory support in, as bridge to recovery, 582–584
    as bridge to transplantation, 581–582
    permanent implantation of, 584–587
  surgical management of, **567–592**
  with normal systolic function, **489–511**
    definitions in, 493
    diagnosis and evaluation in, 496–497
    epidemiology of, 493–494
    general approach to management of, 501–503
    pathophysiology of, 494–496
    pharmacologic therapy in, 499–501
    prognosis in, 497–499
  with systolic dysfunction, outlook in, 530
Heart rate, control of, in atrial fibrillation, 599–601
  with aging, 427, 428
Hip fracture, malnourishment and, 827
Home, medical assessment in, 88–91
  physician–patient relationship in, **83–94**
Hospice, barriers to delivery of, in long-term care facilities, 214–217
Hospice care, 876
  criteria for, 877
  in dementia, 264–265
  in long-term care environments, **211–223**
  Medicare and, 877, 878
Hospitalization, and urinary incontinence in heart failure patients, 643–644
  communication during, patterns of, 113
    structure of, 111–113
  in dementia, 260
  of older patient, patient–physician communication in, 33–34, **109–118**

Hospitals, acute care, step-down units in, 775–776
House call(s), 84, 86
case history illustrating, 87–88
expectations from, 86
gaining trust of patient and caregivers during, 89
Hydration, in dying patient with advanced malignancy, 315–318
in terminal illness, **313–325**
Hydrocolloid dressings, 793–795
Hydrogels, 793
Hygiene, in end-stage disease, 883–884
Hyperglycemic hyperosmolar nonketotic syndrome, 843–844
Hypertension, diabetes as risk factor for, 846–847
Hypoglycemia, 844–845

Illness, acute, in subacute patients, protocol for managing, 690–694
terminal. See *Terminal illness*.
Infection, and antibiotic-resistant microorganisms, in subacute care, 809–812
control of, in subacute care, **805–816**
future considerations in, 814–815
recommendations for, in long-term care facilities, 811–812
definitions of, 806
endemic occurrence of, analysis of, 807
identification of, 806–807
isolation procedures in, in subacute care, 808–812
outbreaks of, in long-term care facilities, management of, 812–813
surveillance for, in subacute care, 806, 807–808
Influenza, control and prevention of, in long-term care facilities, 813
Information, sharing of, barriers to, in managed care, 146–147
withholding of, in managed care, 147
Informed consent, and gag rules imposed by managed care, 147–148
Inotropic drugs, in heart failure complicating acute myocardial infarction, 542
Inotropic reserve, assessment of, in heart failure, 555
Inquiry, process of, 72, 73
Insulin, lispro human, 842
requirements for, in diabetes, 834, 839, 841–843
Intensive care unit, acute ventilator support in, 739–740
chronic ventilator dependency in, 740–741
Internet, for physician–older patient communication, 20–21
Intervention trials, to change patient behavior, 63–67
Intravenous fluids, for terminally ill patients, 315–316

Laboratory testing, in subacute care, 715, 716
Language, in dementia, 154–156
modification of, for dementia patient, 160, 168
Lidocaine, 868
Life Care Center of St. Louis, admissions to, and discharges from, 706–713
and rehabilitation continuum of care, 710–712
as freestanding subacute care facility, 703
development of, 703
functional outcomes in, measurement of, 713
interdisciplinary team for, 705–706
medical direction of, 703
nurses in, 704
rehabilitation schedule of, 704–705
rehabilitation services in, 706–710
rehabilitation within, role of nurses in, 712–713
rooms of, 703, 704
services provided by, 708–710
Life expectancy, discussion of, with cancer patients, 182
of adults over age of 65, 178
questions of, in physician–patient communication at end of life, 182
Lifestyle, as factor in heart failure, 478–480
effects of, on cardiovascular aging, 437–441
Literacy, inadequate communication and information processing problems in, 103–105
Living wills, 241, 257–258
Long-term care facilities, acute care, regional weaning centers and, 745–749
as setting for end-of-life care, 211–212
care of dying in, **225–237**
caregiver roles in, 226–230
certified nursing assistants in, 226–230
characteristics of death in, 232–233
decisional capacity of residents of, 225
delivery of hospice in, barriers to, 214–217
dying in, nursing home caregivers' perspectives on, 230–235
effect of, as site of care, 231
end-of-life care in, ethical issues in, 219–221

Long-term care facilities (*continued*)
opportunities for improving, 217–219
problems associated with, 220–221
focus group process in, 230–231
hospice care in, **211–223**
infection outbreaks in, management of, 812–813
influenza control and prevention in, 813
initial admission screening in, 813
medical decision making in, 220
nurses in, 227
nursing needs of residents of, 227
pain assessment and management in, 272–273
palliative care needs in, 212–214
physicians in, 228–230
recommendations for infection control in, 811–812
tuberculosis control in, 814
ventilator dependency in, 749–750
Long-term care population, predicting death in, 231–232
Lorazepam, in delirium, 365, 377
in pain management, 282

Magnesium, in heart failure complicating acute myocardial infarction, 541–542
Malignancy, advanced, hydration of dying patients with, 315–318
Malnutrition, heart failure in elderly and, 645
in diabetes, 848–849
protein energy. See *Protein energy malnutrition.*
Managed care, advocates of, and benefits of, 134
and geriatric patient–physician relationship, **133–151**
explanations and interactions under, examples of, 135–138
financial and organizational issues associated with, 139–142
gag rules imposed by, 147
informed consent and, 147–148
information sharing in, barriers to, 146–147
limitation of services under, due to ageist attitude, 141
medicopolitical struggle and, 148–149
new and innovative care approaches to, 19–21
physician as advocate for patient under, 138–139
primary care practitioners as double agents in, 134
primary care practitioners as "gatekeepers" in, 134
tight scheduling under, time spent on social concerns and, 144–145
withholding information in, 147
Medicaid changes, under Balanced Budget Act, 758, 765–766
Medical assessment, in home, 88–91
Medical encounter, geriatric, caregiving issues in, **51–60**
Medical Outcomes Study, 98
Medicare payments, Balanced Budget Act and, 758
Medications, appetite-enhancing, 825
as cause of weight loss, 824
effects on communication, 162, 170
implicated in delirium, 272
in heart failure caused by systolic dysfunction, 515–530
and side effects of, 527–528
in pain management, placebos and, 862
routes of administration of, 861
subcutaneous infusion of, 886
timing of administration of, 861–862
number and dosing of, patient adherence and, 29
pseudoaddiction to, 866
use of, in subacute care, 714–715
Medicine, geriatric, 4–5
Megestrol acetate, 825
Memorial Delirium Assessment Scale, 290–293, 362
Metformin, in diabetes, 840–841
Methadone, in pain management, 277–278
Methotrimeprazine, in delirium, 366
Methylphenidate, in depression, 351
Mexiletine, 868
Midazolam, in pain management, 282
Mini-Mental State Examination, 361–362
Mini-Nutritional Assessment, 821–822
Minnesota Model of subacute care, **725–734**
as integrated system, 726–727
challenges of, 731–732
costs of, 731
diagnosis and destinations of patients in, 727–728
nurse practitioner–geriatrician team for, 729–731
outcomes of, 732–734
subacute facility for, requirements for, 728–729
Mitral regurgitation, treatment in, 576–577
Mitral valve inflow analysis, assessment of, in heart failure in elderly, 468–471
Mitral valvuloplasty, percutaneous balloon, for mitral stenosis, 558–561
Monoamine oxidase A, reversible inhibitors of, in depression, 349
Monoamine oxidase inhibitors, in depression, 351

Morphine, in heart failure complicating acute myocardial infarction, 537
in pain management, 277
Myocardial infarction, acute, heart failure complicating, **535–547**
angiotensin-converting enzyme inhibitors in, 538–539
β-blockers in, 540–541
calcium channel blockers and magnesium in, 541–542
digoxin in, 542
diuretics in, 537–538
general measures in, 536
hemodynamic monitoring in, 536
inotropic drugs in, 542
mechanical complications in, 543
morphine in, 537
nitroglycerin in, 538
oxygen therapy in, 536–537
spironolactone in, 540
treatment of arrhythmias in, 542–543
Myocardial perfusion imaging, rest redistribution thallium, 554
sestamibi technetium-99m, 554–555
stress-redistribution thallium-201, 553–554
Myocardium, composition of, age-related changes in, 490
contractility of, with aging, 425–426
viability of, assessment of, in heart failure, 552–555
Myoclonus, opioid change in, 283

National Hospice Organization, dementia and, 382
guidelines for prognosis in chronic diseases, 877, 878
Nausea, as complication of opioids, 865
opioid-induced, management of, 281
Necrotic debris, removal of, in wound healing, 788–789
Neuroleptics, in delirium, 367
in pain management, 283
Neuropathy, peripheral, and heart failure in elderly, 639
Neuropsychiatric complications, in elderly with heart disease, 650
Nitroglycerin, in heart failure complicating acute myocardial infarction, 538
Nonpharmacologic modalities, in atrial fibrillation, 600–601
Nonpharmacologic treatment, of heart failure in elderly, **477–487**
Nonsteroidal anti-inflammatory drugs, for older adults, 275
monitoring in, 275–284
in pain management, 862–864, 883
side effects of, 863
Nonsulfonylurea insulin secretagogues, 840
Norepinephrine dopamine modulators, in depression, 348–349
Nortriptyline, in depression, 349–350
Nurse(s), as team leaders in nursing home, 234
in long-term care facilities, 227
Nursing home residents, and their doctors, study of, discussion of, 127–130
facility used in, 121–122
participants in, and data collection in, 122
results of, 124–127
strategy of analysis in, 122–124
what they value in them, **119–132**
field interviews with, concepts derived from, categories and frequency of, 124–126
Nursing homes. See also *Long-term care facilities.*
and subacute care, compared, 714–715
death and dying in, 875
residents of, pain in, 880
Nutrition, as factor in healing of pressure sores, 785–786
in terminal illness, **313–325**
peripheral parenteral, 825, 826
Nutritional concerns, in elderly patient, 479
Nutritional deficits, correction of, in wound therapy, 785–786
Nutritional disorders, heart failure in elderly and, 644–645
Nutritional problems, in subacute care, management of, **817–831**
Nutritional therapy, for diabetic ulcers, 786

Obesity, control of, in heart failure, 479
Octreotide, in gastrointestinal obstruction, 331–332
Olanzapine, in delirium, 376
Older patient(s), and caregiver, relationship of, perception of, 17
and physician(s), **1–24**
and third person at medical encounter, 7
communication between. See *Older patient–physician communication.*
interactions of, and patient outcomes, studies linking, 11–12
natural history of, understanding of, 12–13
medical encounters of, studies of content of, 8–9
studies of interactional processes of, 9–11
relationship between. See *Older patient–physician relationship.*

Older patient(s) (*continued*)
clinical pragmatism, ethics consultation and, **71–81**
communications patterns of, 98–100
biomedical, 98–99
biopsychosocial, 99
consumerist, 99–100
psychosocial, 99
decisions and factors affecting choices of, physicians' prediction of, 186–187
desire to speak to physician about end-of-life issues, 179–180
dying, as different from younger counterparts, 194–195
depression in, **335–356**
homebound, 84–85
expectations of, 86
hospitalized, and physician, communication between, **109–118**
in nursing homes. See *Nursing home residents.*
multiple medical problems in, and treatment of, 4
outpatient medical encounter and, **95–107**
talking with, about advance directives, **239–254**
who should make decisions for, attitudes about, 187–189
with dementia, advance directives and, **255–268**
Older patient–physician communication, **1–204**
at end of life. See *End of life, physician–older patient communication at.*
distinctive features affecting, 2
emotional health outcomes and, 31–32
hospitalization and, 33–34
in hospitalization, **109–118**
influence of, on health and health-related outcomes, **25–36**
Internet for, 20–21
on social problems, 142–146
patient adherence and, 29–30
patient decision-making and, 27–28
patient recall and, 28–29
patient satisfaction and, 30–31
physical health outcomes and, 32–33
Older patient–physician relationship, and news from poems, 40–44
as alliance with benetits for both parties, patients illustrating, 44–48
clinical, research in development of, 38–40
future directions in, 49
managed care and. See *Managed care.*
nature of, 96–97
seasons of, **37–50**
strategies for improving, 13
studies of, 8
Opioids, addiction to, 866
continuous infusion of, 868
for older adults, 276–278
in pain management, 864–866, 884
side effects induced by, management of, 280–283
withdrawal symptoms, 865–866
Osteomyelitis, complicating pressure ulcers, 798
Outcomes, health-related, influence of patient–physician communication on, **25–36**
Outpatient medical encounter, and elderly patients, **95–107**
Oxycodone, in pain management, 277
Oxygen therapy, in heart failure complicating acute myocardial infarction, 536–537

P450 enzymes, drugs metabolized by, 346
Pain, assessment of, 880–881
in cognitive impairment, 859–860
in pain management, 269–270
proxies in, 860–861
behavioral therapy in, 870
cognitive therapy in, 869–870
depression and, 341
exercises in, 869
functional status examination in, 855–856
history taking in, 854–855
in advanced dementia, 378
in residents of nursing homes, 880
neuropathic, adjuvants for, 283
management of, 867–868
nondrug management of, 869–870
physical examination in, 855
prevalence of, and common etiologies of, 881
psychologic and social assessment in, 856
relief of, in end-of-life care, 881
in wound therapy, 785
total, dimensions of, 887–888
types of, 882
Pain assessment scales, multidimensional, 856–859
unidimensional, 856, 857, 859
Pain management, 273–274
advances in, for older adults, **269–311**
as ethical and legal issue, 883
assessment of delirium in, 271–272
assessment of spiritual or existential distress in, 270
in dementia, 272
in subacute care, **853–873**
analgesic medications in, 861–868

assessment of pain in, 853, 854–861
establishment of treatment plan for, 854
nonpharmacologic methods of, 273
pain assessment in, 269–273
pharmacologic therapy in, 273–275
pharmacokinetic and pharmacodynamic considerations for, 273–274
Palliative care, 875–876
at end of life, 198
concerns in, addressing of, 220
definition of, 175
in end-stage dementia, specific challenges in, 382–384
in long-term care facilities, 212–214
training in, 175
Palliative care setting, depression in, assessment of, 337–338
Parenteral nutrition, peripheral, 825, 826
Passive ventricular constraint, in ischemic cardiomyopathy, 575
Patient(s), adherence to recommended treatment, in pataient self-management, 62–63
behavior of, intervention trials to change, 63–67
decision making by, criteria for, 184–185
older. See *Older patient(s).*
placement and transfer, improving process of, 695–696
Patient Self Determination Act, 180
Pemoline, in depression, 351
Percutaneous endoscopic gastrostomy tube, adverse consequences of, 319
aspiration pneumonia and, 319–320
guidelines for placement of, 321
prolonging life with, 318–319
Physical disability, depression and, 341–342
Physical health outcomes, patient–physician communication and, 32–33
Physician(s), behavior of, regarding principles defining disclosure, 181–182
characteristics of, as influence on patient adherence, 62
desire of patient to speak to, about end-of-life issues, 179–180
in long-term care facilities, 228–230
in process of dying, 234
of nursing home residents, what patients value about them, **119–132**
older patients and, **1–24**
communication between. See *Older patient–physician communication.*
interactions of, and patient outcomes, studies linking, 11–12
natural history of, understanding of, 12–13
medical encounters of, studies of content of, 8–9
studies of interactional processes of, 9–11
relationship of. See *Older patient–physician relationship.*
prediction of, on decisions and factors affecting choices of patients, 186–187
reimbursement of, for subacute care, 698
roles and relationships of, with dementia patient, 164, 173
time constraints of, and patient communication, 62
understanding of patient's perspective by, 14–15
Physician–patient relationship, in home, **83–94**
power dynamic in, 85–86
Physicians for a National Health Program, 148–149
Pneumonia, aspiration, percutaneous endoscopic gastrostomy tube and, 319–320
in subacute patients, protocol for managing, 690–694
treatment for, study of patient preferences in, 184–185
Polypharmacy, heart failure in elderly and, 639–641
Positron emission tomography, to assess myocardial viability, 552–553
Postacute care, wound management in, **783–803**
Poststroke units, 777
Postural hypotension, associated with heart failure in elderly, 633–634
Power dynamic, in physician–patient relationship, 85–86
Powers of attorney for health care. See *Health care proxy.*
Practical nurse, licensed, in long-term care facility, 227
Presbycusis, 5
and heart failure in elderly, 637–638
Pressure ulcers, bacteremia from, 797
differential diagnosis of, 784
healing of, nutrition in, 785–786
rates of, 783, 784
maintenance of moist environment in, 786–787
mortality associated with, 796–797
osteomyelitis complicating, 798
prevention and healing of, in subacute care, 716
promotion of wound healing in, 790–791
protection from bacterial contamination, 792–793
removal of necrotic debris from, 789

Pressure ulcers (*continued*)
shielding of, from further damage, 787–788
surgical management of, 795–796
topical wound dressing for, 793–795
Propofol, in delirium, 366
Protein energy malnutrition, causes of, 823–824
diagnosis of, 821
effects of, 820–821
in subacute care, 716, 823
management of, 825, 826
Proxy directives, 241, 257–258
Psychiatric comorbidity, in elderly with heart disease, 650
Psychosocial considerations, in heart failure in elderly, **649–661**
Psychostimulants, 282
in depression, 350
Pulmonary vein analysis, in heart failure in elderly, 468–471

Quality of life, health-related, in elderly with heart disease, 656–657

Radiation therapy, in pain management, in bone metastasis, 283–284
Radiopharmaceuticals, in pain management, 284
Recall, of complex treatment regimens, 102–103
Registered nurse, in long-term care facility, 227
Rehabilitation, acute, and geriatric care, future of, 781
cardiac, and secondary prevention programs, for elderly cardiac patients, **619–629**
in elderly, data demonstrating feasibility of, 624–625
future role of, 626
in historical context, 619–620
in subacute care units, 701
requirements for, prospective payment system, 764
Rehabilitation services, acute, in geriatric evaluation and management units, effectiveness of, **775–782**
Relaxation therapy, in pain management, 273
Respiratory failure, recovery from, in elderly versus younger patients, 737, 738
Revascularization, in absence of angina, 550–551
Risperidone, in delirium, 366, 376

Samarium-153-lexidronam, in pain management, 284
Saropenia, 820
Scopolamine, in gastrointestinal obstruction, 331
Selective serotonin reuptake inhibitors, in depression, 344–347
Self-management, patient, adherence to recommended treatment for, 62–63
Sensory deficits, 5
Sensory deprivation syndromes, age-related, 638
Sensory impairments, age-related, influence on communication, 161, 169–170
Sensory limitations, attention to, 16–17
Serotonin antagonist reuptake inhibitors, in depression, 348
Serotonin norepinephrine reuptake inhibitors, in depression, 347–348
Sestamibi technetium-99m myocardial perfusion imaging, 554–555
Shortness of breath, in end-stage disease, 883
Sinus rhythm, maintenance of, in arrhythmias, 601–604
versus rate-control, in arrhythmias, 604–605
Skilled nursing facilities, prospective payment system for, Balanced Budget Act and, 763
Sleep, in advanced dementia, 379
Smell, decline in ability to, 817
Social problems, patient–doctor communication on, 142–146
and intervention by doctor, 144
case history of, 142–144
Social support, in elderly with heart disease, 656
Sodium restriction, in heart failure, 478
Somatostatin, in gastrointestinal obstruction, 331
Speech, adjustments to, for dementia patient, 160–161, 169, 173
in dementia, 154–156
deterioration of, 154
Speech-language pathologists, and dementia, 157
Spiritual distress, indicators of, 271
Spironolactone, in heart failure complicating acute myocardial infarction, 540
Staphylococcus aureus, isolation procedures in, in subacute care, 809–810
Step-down units, in acute care hospitals, 775–776
Steroids, mental disturbances caused by, 363
Stroke, dysphagic, or advanced dementia, tube feeding in, 318–321
prevention of, in atrial fibrillation, 599–601

Strontium-89, in pain management, 284
Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment (SUPPORT), 671–672
Subacute care, and nursing homes, compared, 714–715
definition of, 683–685, 777
of Joint Commission of Accreditation of Healthcare Organizations, 725–726
facility for, and physician reimbursement, 698
and reimbursement for patient, 697–698
delivery of, processes relevant to, 685–686, 687
proper provision of, requirements for, 685–688
for seniors, **683–893**
future of, **683–699**
infection control in, **805–816**
laboratory testing in, 715, 716
levels of, in acute illness and injury, 688–689
Life Care Center of St. Louis experience with, **701–724**
medication use in, 714–715
Minnesota Model of. See *Minnesota Model of subacute care.*
nutritional problems in, management of, **817–831**
pain management in, **853–873**
protein energy malnutrition in, 823
protocol for managing pneumonia patients in, 690–694
rational clinical approaches to clinical issues in, 688–695
reimbursement for, ensuring of, 696–698
special conditions in, 715–717
Subacute care unit(s), admitting diagnoses for, 778–779
advances and disadvantages of, 779
characteristics of, 777–781
cost of care in, 702
evaluations of, 780–781
increase in use of, 777, 778
management of diabetes mellitus in, **833–852**
medical diseases and functional status as focus of, 701, 702
rehabilitation in, 701
subacute care regimen in, for geriatric patients, 779
team in, 779
types of, 777–778
Substance abuse, in elderly with heart disease, 650–651
Sulfonylurea insulin secretagogues, 840
Surrogate decision makers, 241
Systolic and diastolic function, normal, heart failure in, 471
Systolic dysfunction, heart failure in elderly caused by, drug therapy of, **513–534**
Systolic function, normal, heart failure with. See *Heart failure, with normal systolic function.*
Systolic versus diastolic dysfunction, in heart failure in elderly, 452–454

Taste, decline in ability to, 817
Team approach, to manage patient care, 91–92
case history of, 92–93
Telemedicine, 20
Telephone communication, 19
Terminal illness, delirium in, **357–372**
depression in, 336–339
management of, 343
nutrition and hydration in, **313–325**
Test of Functional Health Literacy Assessment, 104
Thallium-201 stress-redistribution myocardial perfusion imaging, 553–554
Thallium rest redistribution myocardial perfusion imaging, 554
Thiazolidinediones, in diabetes, 841
Tobacco abuse, in elderly with heart disease, 650–651
Topical wound dressing, choosing of, 793–795
Trace mineral deficiencies, 827
Tramadol, in pain management, 276–277
Transfer rule provisions, Balanced Budget Act and, 760
Treatment regimens, complex, recall challenges of, 102–103
Tricyclic antidepressants, in depression, 349–350
Truth telling, by physician, at end of life, 180–182, 197
Tube feeding, 825, 826
in advanced dementia or dysphagic stroke, 318–321
Tuberculosis, control of, in long-term care facilities, 814

Undernutrition syndromes, heart failure in elderly and, 645
Urinary incontinence, and heart failure in elderly, 641–644
management of, 885

Valvular stenosis, congestive heart failure in, 555–561

Vasculature, aging, structure of, 422
Vasodilators, in heart failure caused by systolic dysfunction, 524
Ventilator dependence, chronic, disposition and, 736
duration of care and, 735
Health Care Financing Administration definition of, 735
in elderly, **735–755**
prevention of, 751–752
in intensive care unit, 740–741
life-sustaining therapy and, 750–751
outcomes of, 738–739
outcomes of weaning and, 735–736
process of, and site of care, 739
severity of critical illness and, 735
survival and, 736
in long-term care facilities, 749–750
prolonged, management of, in noninvasive respiratory care units, 742–744
in special hospitals and long-term acute care, 746–747
Ventilator-dependent unit(s), 741–745
and intensive care unit, cost of care in, compared, 744–745
Ventricular arrhythmias, nonsustained, incidence, prognosis, and treatment of, 606–608
sustained, incidence, prognosis, and treatment of, 605–606
Vision, impairment of, and heart failure in elderly, 638–639
loss of, communication and, 5
Vitamin B_{12} deficiency, 826–827

Warfarin, for stroke prevention in atrial fibrillation, 597–599
Weaning centers, regional, long-term acute care and, 745–749
Weight loss, medications as cause of, 842
World Health Organization, analgesic ladder of, 274
Wound dressing(s), occlusive, compared, 793, 794
topical, choosing of, 793–795
Wound healing, in chronic and acute wounds, compared, 783
promotion of granulation tissue in, 789–791
surgical management of, 795–796
Wound management, in postacute care, **783–803**
Wound therapy, correction of nutritional deficits in, 785
general principles of, 785–793
pain relief in, 785
removal of necrotic debris in, 788–789
Wounds, chronic, and acute, healing in, compared, 783
complications of, 796–798
environment, moist, maintenance of, 786–787
protection of, from bacterial contamination, 791–793
shielding of, from further damage, 787

Zinc deficiency, 827